In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts

Bumped kinase inhibitors (BKIs) target the apicomplexan calcium-dependent protein kinase 1 (CDPK1). BKI-1748, a 5-aminopyrazole-4-carboxamide compound when added to fibroblast cells concomitantly to the time of infection, inhibited proliferation of apicomplexan parasites at EC(50)s of 165 nM (Neospo...

Descripción completa

Detalles Bibliográficos
Autores principales: Imhof, Dennis, Anghel, Nicoleta, Winzer, Pablo, Balmer, Vreni, Ramseier, Jessica, Hänggeli, Kai, Choi, Ryan, Hulverson, Matthew A., Whitman, Grant R., Arnold, Samuel L.M., Ojo, Kayode K., Van Voorhis, Wesley C., Doggett, J. Stone, Ortega-Mora, Luis M., Hemphill, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Regular article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144743/
https://www.ncbi.nlm.nih.gov/pubmed/34030110
http://dx.doi.org/10.1016/j.ijpddr.2021.05.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144743/
https://www.ncbi.nlm.nih.gov/pubmed/34030110
http://dx.doi.org/10.1016/j.ijpddr.2021.05.001

Ejemplares similares